Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$102.50 USD

102.50
9,365,005

-2.33 (-2.22%)

Updated Oct 31, 2024 01:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tirthankar Chakraborty headshot

4 Blue-Chip Stocks to Buy as Dow Seals Record October Gains

by Tirthankar Chakraborty

With the Dow witnessing a sharp run-up in October, investing in stocks like Caterpillar (CAT), JPMorgan (JPM), Home Depot (HD) and Merck (MRK) seems prudent.

    Merck (MRK) Upgraded to Buy: Here's Why

    by Zacks Equity Research

    Merck (MRK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised

    by Zacks Equity Research

    Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.

    Kinjel Shah headshot

    Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod

    by Kinjel Shah

    Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.

    Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Investors will likely focus on the progress of Moderna's (MRNA) late-stage pipeline candidates during the third-quarter earnings call, which can lower its dependence on COVID vaccine sales.

    Company News for Oct 28, 2022

    by Zacks Equity Research

    Companies in The News Are: MRK,SHOP,NOC,LUV

    Seagen's (SGEN) Q3 Earnings Miss, Revenues Surpass Estimates

    by Zacks Equity Research

    Seagen (SGEN) reports a wider-than-expected loss in the third quarter of 2022 while its revenues beat estimates. The company raises total revenue guidance for 2022.

    Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View

    by Zacks Equity Research

    Merck (MRK) beats Q3 estimates for earnings and sales. The company continues to see robust growth in Keytruda and Gardasil sales.

    Merck (MRK) Q3 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Merck (MRK) delivered earnings and revenue surprises of 10.78% and 6.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More

    by Zacks Equity Research

    Let's analyze how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Oct 27.

    Merck (MRK) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q3 earnings.

      AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

      by Zacks Equity Research

      AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Corcept (CORT) Thrives on Korlym, Overdependence a Concern

      by Zacks Equity Research

      Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

        Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline

        by Zacks Equity Research

        Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

        Merck (MRK) Dips More Than Broader Markets: What You Should Know

        by Zacks Equity Research

        Merck (MRK) closed the most recent trading day at $93.26, moving -1.43% from the previous trading session.

        Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

        by Zacks Equity Research

        Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

        Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?

        by Zacks Equity Research

        Smart Beta ETF report for DJD

        The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK

        by Zacks Equity Research

        Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.

        Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab

        by Zacks Equity Research

        Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.

        Kinjel Shah headshot

        Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab

        by Kinjel Shah

        FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.

        Here's Why Merck (MRK) is a Strong Value Stock

        by Zacks Equity Research

        Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

        Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS

        by Zacks Equity Research

        Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.

        Merck (MRK) Gains As Market Dips: What You Should Know

        by Zacks Equity Research

        In the latest trading session, Merck (MRK) closed at $91.05, marking a +0.63% move from the previous day.

        Merck (MRK) Posts Positive Results From PAH Drug Study

        by Zacks Equity Research

        Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.

        Stock Market News for Oct 10, 2022

        by Zacks Equity Research

        U.S. stock markets closed sharply lower on Friday following stronger-than-expected job data for September.